Literature DB >> 9303410

In vitro activity of trovafloxacin against Chlamydia pneumoniae.

P M Roblin1, A Kutlin, M R Hammerschlag.   

Abstract

The in vitro susceptibilities of 12 strains of Chlamydia pneumoniae to a new quinolone, trovafloxacin, and ofloxacin, doxycycline, erythromycin, and azithromycin were determined. The activity of trovafloxacin was similar to that of ofloxacin, with a MIC at which 90% of the isolates are inhibited and a minimal concentration at which 90% of the isolates are killed of 1.0 microg/ml, but trovafloxacin was less active than doxycycline, erythromycin, and azithromycin.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9303410      PMCID： PMC164061          DOI： 10.1128/AAC.41.9.2033

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors:  M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

2.  Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

3.  In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.

Authors:  F Crokaert; M Aoun; V Duchateau; P Grenier; A Vandermies; J Klastersky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

4.  Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.

Authors:  J F Plouffe; M T Herbert; T M File; I Baird; J N Parsons; J B Kahn; K T Rielly-Gauvin
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.

Authors:  B A Lipsky; K J Tack; C C Kuo; S P Wang; J T Grayston
Journal:  Am J Med       Date:  1990-12       Impact factor: 4.965

6.  Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.

Authors:  K S Thomson; S A Chartrand; C C Sanders; S L Block
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 7.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

8.  In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; C L Hyman; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

9.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.

Authors:  R Teng; T E Liston; S C Harris
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790
View more
  9 in total

1.  In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

2.  In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.

Authors:  P M Roblin; T Reznik; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 5.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Activity of quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 7.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Authors:  J C Pechère; T D Gootz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

9.  Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.

Authors:  F Trémolières; F de Kock; N Pluck; R Daniel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.